Vermillion Summarizes Recent Accomplishments and 2007 Financial Results; Outlines 2008 Business ...(d disease detection classification...)

detection, classification and monitoring of prevalent cancers,

including ovarian, breast and prostate. Vermillion will have access to

exclusive commercial rights to the discoveries made through the

partnership.

-- Vermillion's stockholders and board of directors approved a 1 for 10

reverse stock split of the Company's common stock. The reverse split

became effective at the close of trading on Monday, March 3, 2008.

-- The Ohio State University commercially launched Vermillion's diagnostic

test for managing patients with TTP, a hematological disease. The test

helps physicians make the correct diagnosis, initiate timely treatment,

evaluate response to therapy and predict the risk of recurrence in

patients with TTP.

-- Received issuance of U.S. Patent No. 7,297,556 for aiding diagnosis of

nephrotic syndrome, a kidney disorder marked by very high or low levels

of protein in the urine, which results in bodily swelling and high

cholesterol.

2008 Milestones

The Company's primary goal for 2008 will be to commercialize its diagnostic tests through collaborations with Quest Diagnostics and other thought leaders in oncology, cardiology and hematology. Vermillion expects to attain the following milestones:

-- Present data from three studies highlighting progress in Vermillion's

ovarian cancer diagnostic program at the Society for Gynecologic

Oncologists' (SGO) 2008 Annual Meeting on Women's Cancer held

March 9-12 in Tampa, Florida.

-- Report top-line data from the ovarian tumor triage clinical trial later

this quarter and submit to the U.S. Food and Drug Administration (FDA)

for clearance as an in vitro diagnostic test in the first half of 2008.

-- Work with Quest Diagnostics to integrate Vermillion's PAD proteomic

biomarkers as a laboratory
'/>"/>